Skip to Content
MDPIMDPI

Advanced

Sci. Pharm.Scientia Pharmaceutica
PDF
  • Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
  • Abstract
  • Open Access

16 April 2009

1 Page

Functionability of NMDA-Receptors in an in vitro model of the Blood-Brain-Barrier

,
,
,
and
1
Department of Medicinal Chemistry, University of Vienna, Althanstraße 14, 1090 Vienna, Austria
2
PharmaCon GmbH, Riglergasse 4/5, 1180 Vienna, Austria
3
Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, Althanstraße 14, 1090 Vienna, Austria
*
Author to whom correspondence should be addressed.
Sci. Pharm.2009, 77(7), 218;https://doi.org/10.3797/scipharm.oephg.21.PO-19
Version Notes
Order Reprints

Abstract

A diversity of disease processes and conditions such as Alzheimer´s disease, schizophrenia, epilepsy and stroke – although they are caused by different mechanism – share one common target: the NMDA-receptor [1]. Recent studies reported the presence and the participation of this glutamate-gated ion-channel in major regulatory mechanisms at the blood-brain barrier (BBB). In order to show the functionability of this receptor and his effects on the BBB, we used an in vitro model based on human cell line ECV304 [2].

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
Synthesis of a Building Block for Oligopeptide-Oligonucleotide Conjugates
Previous
Functionality of P-glycoprotein in the Blood-Brain Barrier Mimicking Cell Line PBMEC/C1-2
Next